Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism

E Muñoz, E Tolosa, P Pastor, M J Martí, F Valldeoriola, J Campdelacreu, R Oliva

Background: Autosomal recessive juvenile parkinsonism is a neurodegenerative disorder associated with mutations in the parkin gene.

Objectives: To search for the presence of parkin gene mutations in Spanish patients with Parkinson’s disease (PD) and characterise the phenotype associated with these mutations.

Methods: Thirty seven PD patients with either early onset or autosomal recessive pattern of inheritance were selected for genetic study.

Results: Mutations were identified in seven index patients (19%). Homozygous mutations were detected in six patients and a heterozygous mutation in one. The age at onset was lower in patients with mutations than in patients without mutations. Dystonia at onset was present in two patients with parkin gene mutations. The disease began in two patients with postural tremor in the upper limbs mimicking essential tremor. Four patients exhibited a long term response to dopamine agonists. The c.255delA mutation was identified in four unrelated families. This is a frameshift mutation leading to protein truncation.

Conclusions: Parkin gene mutations are present in Spanish patients with early onset and/or an autosomal recessive parkinsonism. The c.255delA is the most frequent mutation found, suggesting a relative high prevalence in the Spanish population.

RESULTS

We identified 37 index patients (17 women, 20 men) fulfilling the criteria proposed for the screening of mutations in the parkin gene. Twenty four were familial PD cases, with other siblings affected, and 13 were sporadic early onset PD cases.

Parkin gene mutations were found in seven index patients (19%; table). Six patients had homozygous mutations that consisted of two frameshift mutations (c.255delA found in four patients and c.972delG found in one patient) and one exon rearrangement (exon 5–6del). One patient had a heterozygous mutation (Val15Met). We sequenced the coding region of parkin gene in this patient and his brother, who also carried the mutation and was affected by the disease, but we did not find any other mutations. The Val15Met mutation was not found in 120 chromosomes belonging to 30 PD patients and 30 healthy control subjects, supporting the fact that this could be a new missense mutation. In addition to these mutations, we identified two polymorphisms in our patients. Val/Leu380 was found in two unrelated families with late onset parkinsonism and Asp/Asn394 in a patient with sporadic juvenile onset parkinsonism.

MATERIALS AND METHODS

Subjects

Patients fulfilling the clinical diagnostic criteria for PD proposed by the UK Parkinson’s Disease Society Brain Bank, except for the exclusion criteria of familial disorder, were recruited from the PD Movement Disorder Unit of the Hospital Clinic of Barcelona. Control subjects were recruited among healthy donors without familial history of PD or tremor.

Parkinsonian patients with either age at onset ≤40 years or an autosomal recessive pattern of inheritance were selected for genetic study. The study was approved by the ethics committee of our hospital.

Genetic study

DNA was isolated from patients’ leucocytes by standard procedures. The different exons of the parkin gene were amplified by polymerase chain reaction (PCR) using primers and conditions as described. A single strand conformational polymorphism (SSCP) analysis of the PCR products was carried out through electrophoresis in two different conditions: 7.5% polyacrylamide gel at room temperature and 12% polyacrylamide gel at 4°C. The bands were visualised after silver staining. PCR products with an abnormal motility pattern were sequenced. The normal cDNA sequence of parkin gene (DNA Data Bank of Japan: AB009973) was obtained from the GenBank database (http://www.ncbi.nlm.nih.gov/Genbank).

Statistical assessment

Means were compared with the non-parametric Mann-Whitney U test. Frequencies were compared with the χ² test.

Abbreviations: PD, Parkinson’s disease; PCR, polymerase chain reaction; SSCP, single strand conformational polymorphism; UPDRS, unified Parkinson’s disease rating scale.
Two of seven patients with parkin gene mutations were sporadic cases. Six patients were Spanish and one came from Morocco (PK-11). The mean age at onset (SD) was 32.8 (8.6) years in patients with mutations and 44.4 (15) years in patients without mutations (p = 0.02). Dystonia was only found in two patients with parkin gene mutations. These patients developed the disease at the age of 20 and 30 years, respectively. All patients had a good response to levodopa and/or other dopamine agonists. The mean (SD) motor score of the unified Parkinson’s disease rating scale (UPDRS) in the “on” stage was 23.4 (8.6). One of three patients (PK-205) treated with levodopa showed choreiform “on” dyskinesias.

c.255delA mutation

The c.255delA mutation was found in four unrelated patients. All patients but one were living in Barcelona but they were originally from different regions in Spain. Parents’ consanguinity was confirmed only in one case (patient PK-21). The age at onset of the disease ranged from 30 to 41 years. All patients developed symmetrical parkinsonian signs (tremor, rigidity, and bradykinesia); however, the clinical features at onset varied among the patients. Only one patient (PK-184) presented with feet dystonia at onset. This patient is now 65 years old and she is treated only with the dopamine agonist bromocriptine. Another patient (PK-21) was initially diagnosed to have essential tremor because for several years he only exhibited postural tremor on his hands that responded partially to propanolol. He is now treated with very low doses of levodopa and selegiline. The third patient (PK-131) began her disease with tremor in the upper limbs, which was present at rest but increased in frequency notably when she held the arms outstretched. The last patient (PK-201) presented with slow gait and short steps and had an excellent response to bromocriptine, trihexyphenidyl, and selegiline, eight years after disease onset.

The genetic study of siblings of patients PK-21 and PK-131 lead us to identify heterozygous and homozygous carriers of the mutation. One homozygous carrier (L97–516) was a 47 year old woman who was the sister of patient PK-21. She did not present parkinsonian signs at the time of examination. However, another homozygous carrier (L00–379), a 42 year old woman, who was the sister of patient PK-131 and had not previously been diagnosed with PD, showed bradykinesia and slight symmetrical rigidity on the extremities, associated with slight postural tremor on her hands. None of the heterozygous carriers of the mutation presented parkinsonian signs.

Both homozygous and heterozygous mutated alleles showed a clear and reproducible pattern of bands by SSCP that were different from those obtained for normal alleles (fig 1). Thus, we considered that SSCP was an easy method to investigate the presence of the c.255delA mutation in normal subjects in order to estimate the prevalence of this mutation in our population. Subsequently, we screened for the c.255delA mutation in 100 healthy control subjects and found a single subject with an abnormal SSCP pattern suggesting the presence of the mutation in heterozygosity. The mutation was confirmed after sequencing the PCR product. Application of the Hardy-Weinberg principle allowed us to calculate an approximate genetic risk of 1/40 000. We therefore estimate that about 1000 individuals could be homozygous carriers for the mutation in the Spanish population.

DISCUSSION

We found parkin gene mutations in two sporadic early onset PD cases and in five familial PD cases with an autosomal...
recessive pattern of inheritance. The clinical features of our patients lead us to confirm a phenotypic variability in patients with parkin gene mutations.

The age at onset of patients with mutations varied from 20 to 46 years. The mean age at onset was significantly lower in patients with parkin gene mutations than in those without mutations. Similar results have been previously reported by Lucking and colleagues. Only two of our patients presented with foot dystonia at onset. Dystonia has been reported in 42% of patients in a large series of patients with parkin gene mutations. The motor score of the UPDRS with the patients under the effect of medication (“on” situation) showed a mild to moderate parkinsonism. None of the four patients who were only taking dopamine agonists complained of dyskinesias. Two of them have been treated with dopamine agonists for over 15 years. This finding suggests that some patients with parkin gene mutations may respond successfully to dopamine agonists for a long period of time; also, the appearance of dyskinetic movements may be prevented.

The most relevant finding in our study was the presence of the same mutation (c.255delA) in four unrelated Spanish patients, suggesting that this mutation could be relatively frequent in our population. The presence of the mutation in 1 of 200 chromosomes from healthy controls supports this view. We have estimated that the frequency of homozygous carriers for the mutation could be 1/40 000 in Spain. Although we cannot rule out a random effect for our findings, other evidence supports the fact that c.255delA may be a frequent mutation in Europe. This mutation has been described previously in two Spanish patients and in five other European patients. Haplotype analysis of patients from different countries carrying the mutation detected that the mutation segregates with allele 7 of marker D6S1599, which is located 24 kb downstream of exon 2. This finding suggests that the c.255delA mutation is possibly an ancestral European mutation.

The c.255delA is a frameshift mutation that leads to a change into the amino acid sequence starting at codon 52 (Asn52Met), and the appearance of a stop codon (TGA) at position 80 that truncates the parkin protein. The age at onset of the disease in patients carrying this mutation varies from 30 to 41 years in our series. However, we have found this mutation in a healthy 47 year old woman (PK-21 sister). Intrafamilial variability of the age at onset has been reported previously in two Spanish patients and in five other European patients. Haplotype analysis of patients from different countries carrying the mutation detected that the mutation segregates with allele 7 of marker D6S1599, which is located 24 kb downstream of exon 2. This finding suggests that the c.255delA mutation is possibly an ancestral European mutation.

The c.255delA is a frameshift mutation that leads to a change into the amino acid sequence starting at codon 52 (Asn52Met), and the appearance of a stop codon (TGA) at position 80 that truncates the parkin protein. The age at onset of the disease in patients carrying this mutation varies from 30 to 41 years in our series. However, we have found this mutation in a healthy 47 year old woman (PK-21 sister). Intrafamilial variability of the age at onset has been reported previously in two Spanish patients and in five other European patients. Haplotype analysis of patients from different countries carrying the mutation detected that the mutation segregates with allele 7 of marker D6S1599, which is located 24 kb downstream of exon 2. This finding suggests that the c.255delA mutation is possibly an ancestral European mutation.

The most relevant finding in our study was the presence of the same mutation (c.255delA) in four unrelated Spanish patients, suggesting that this mutation could be relatively frequent in our population. The presence of the mutation in 1 of 200 chromosomes from healthy controls supports this view. We have estimated that the frequency of homozygous carriers for the mutation could be 1/40 000 in Spain. Although we cannot rule out a random effect for our findings, other evidence supports the fact that c.255delA may be a frequent mutation in Europe. This mutation has been described previously in two Spanish patients and in five other European patients. Haplotype analysis of patients from different countries carrying the mutation detected that the mutation segregates with allele 7 of marker D6S1599, which is located 24 kb downstream of exon 2. This finding suggests that the c.255delA mutation is possibly an ancestral European mutation.

The c.255delA is a frameshift mutation that leads to a change into the amino acid sequence starting at codon 52 (Asn52Met), and the appearance of a stop codon (TGA) at position 80 that truncates the parkin protein. The age at onset of the disease in patients carrying this mutation varies from 30 to 41 years in our series. However, we have found this mutation in a healthy 47 year old woman (PK-21 sister). Intrafamilial variability of the age at onset has been reported previously in two Spanish patients and in five other European patients. Haplotype analysis of patients from different countries carrying the mutation detected that the mutation segregates with allele 7 of marker D6S1599, which is located 24 kb downstream of exon 2. This finding suggests that the c.255delA mutation is possibly an ancestral European mutation.
Relative high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal recessive parkinsonism

E Muñoz, E Tolosa, P Pastor, M J Martí, F Valdeoriola, J Campdelacreu and R Oliva

J Neurol Neurosurg Psychiatry 2002 73: 582-584
doi: 10.1136/jnnp.73.5.582

Updated information and services can be found at:
http://jnnp.bmj.com/content/73/5/582

These include:

References
This article cites 13 articles, 3 of which you can access for free at:
http://jnnp.bmj.com/content/73/5/582#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Parkinson's disease (690)
- Movement disorders (other than Parkinson's) (766)
- Drugs: CNS (not psychiatric) (1945)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/